A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington’s disease. FDA approved on August 15, 2008.
Prolongation of the QTc interval has been observed at doses of 50 mg. In rats, it has been observed that xenazine or its metabolites bind to melanin-containing tissues such as the eyes and skin. After a single oral dose of radiolabeled xenazine, radioactivity was still detected in eye and fur at 21 days post dosing.
Dose-limiting adverse effects are sedation, parkinsonism, akathsia, and depression. LD50 oral, mouse: 550 mg/kg